Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Oluwaseun Egunsola, Nicholas A. Buckley & Jacques E. Raubenheimer. (2021) Price mark-up on the street sales of prescription pharmaceuticals in Australia. Journal of Substance Use 26:5, pages 483-490.
Read now
Read now
Richard N Rosenthal & Viral V Goradia. (2017) Advances in the delivery of buprenorphine for opioid dependence. Drug Design, Development and Therapy 11, pages 2493-2505.
Read now
Read now
Joji Suzuki, Jennifer Zinser, Mohammed Issa & Claudia Rodriguez. (2017) Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment. Substance Abuse 38:4, pages 504-507.
Read now
Read now
Björn Johnson & Torkel Richert. (2016) A comparison of privileged access interviewing and traditional interviewing methods when studying drug users in treatment. Addiction Research & Theory 24:5, pages 406-415.
Read now
Read now
Michael Soyka. (2015) Buprenorphine–naloxone buccal soluble film for the treatment of opioid dependence: current update. Expert Opinion on Drug Delivery 12:2, pages 339-347.
Read now
Read now
Björn Johnson & Torkel Richert. (2015) Diversion of Methadone and Buprenorphine from Opioid Substitution Treatment: Patients who Regularly Sell or Share Their Medication. Journal of Addictive Diseases 34:1, pages 1-17.
Read now
Read now
Björn Johnson & Torkel Richert. (2014) Diversion of Methadone and Buprenorphine from Opioid Substitution Treatment: A Staff Perspective. Journal of Psychoactive Drugs 46:5, pages 427-435.
Read now
Read now
Helen Baldwin & Paul Duffy. (2013) Drug treatment practitioners’ perceptions of methadone diversion and their responses to it. Drugs: Education, Prevention and Policy 20:1, pages 22-32.
Read now
Read now
Articles from other publishers (25)
Anna Kline, Jill M. Williams, Marc L. Steinberg, Dina Mattern, Megan Chesin, Suzanne Borys & Vamsee Chaguturu. (2023) Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone. Journal of Substance Use and Addiction Treatment 149, pages 209028.
Crossref
Crossref
Jordan M. Hyatt & Philipp P. Lobmaier. (2020) Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation. Health & Justice 8:1.
Crossref
Crossref
Shann Hulme, Caitlin Elizabeth Hughes & Suzanne Nielsen. (2020) The price and mark up of pharmaceutical drugs supplied on the black market. International Journal of Drug Policy 76, pages 102626.
Crossref
Crossref
George C. DertadianGeorge C. Dertadian. 2019. A Fine Line. A Fine Line
73
107
.
Shann Hulme, David Bright & Suzanne Nielsen. (2018) The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis. Drug and Alcohol Dependence 186, pages 242-256.
Crossref
Crossref
Abhishek Ghosh, Debasish Basu & Ajit Avasthi. (2018) Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions. Indian Journal of Psychiatry 60:3, pages 361.
Crossref
Crossref
Cynthia Marie-ClaireClément Jourdaine, Jean-Pierre Lépine, Frank Bellivier, Vanessa BlochFlorence Vorspan. (2017) Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. Pharmacogenomics 18:14, pages 1359-1372.
Crossref
Crossref
George C. Dertadian, Thomas C. Dixon, Jennifer Iversen & Lisa Maher. (2017) Self-limiting non-medical pharmaceutical opioid use among young people in Sydney, Australia: An exploratory study. Drug and Alcohol Review 36:5, pages 643-650.
Crossref
Crossref
Shannon R. Kenney, Bradley J. Anderson, Genie L. Bailey & Michael D. Stein. (2017) The relationship between diversion-related attitudes and sharing and selling buprenorphine. Journal of Substance Abuse Treatment 78, pages 43-47.
Crossref
Crossref
Andrew S. Huhn & Kelly E. Dunn. (2017) Why aren't physicians prescribing more buprenorphine?. Journal of Substance Abuse Treatment 78, pages 1-7.
Crossref
Crossref
Mélanie Kernisant, Jessica Delorme, Jean-Luc Kabore, Georges Brousse, Catherine Laporte, Marie Zenut, Chouki Chenaf & Nicolas Authier. (2016) Diminution de la prévalence du docteur shopping de la buprénorphine entre 2004 et 2014 en France. La Presse Médicale 45:12, pages e369-e375.
Crossref
Crossref
Essiina Launonen, Isla Wallace, Elina Kotovirta, Hannu Alho & Kaarlo Simojoki. (2016) Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients. Drug and Alcohol Dependence 162, pages 227-235.
Crossref
Crossref
Jessica Delorme, Chouki Chenaf, Jean-Luc Kabore, Bruno Pereira, Aurélien Mulliez, Aurore Tremey, Georges Brousse, Marie Zenut, Catherine Laporte & Nicolas Authier. (2016) Incidence of high dosage buprenorphine and methadone shopping behavior in a retrospective cohort of opioid-maintained patients in France. Drug and Alcohol Dependence 162, pages 99-106.
Crossref
Crossref
Bernd Schulte, Christiane S. Schmidt, Lisa Strada, Christine Götzke, Philipp Hiller, Benedikt Fischer & Jens Reimer. (2016) Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany. International Journal of Drug Policy 29, pages 57-65.
Crossref
Crossref
Essiina Launonen, Hannu Alho, Elina Kotovirta, Isla Wallace & Kaarlo Simojoki. (2015) Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. International Journal of Drug Policy 26:9, pages 875-882.
Crossref
Crossref
Björn Johnson & Torkel Richert. (2015) Diversion of Methadone and Buprenorphine from Opioid Substitution Treatment: The Importance of Patients’ Attitudes and Norms. Journal of Substance Abuse Treatment 54, pages 50-55.
Crossref
Crossref
Björn Johnson & Torkel Richert. (2015) Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: Prevalence estimates and risk factors. International Journal of Drug Policy 26:2, pages 183-190.
Crossref
Crossref
Francis Matthew-Simmons & Alison Ritter. (2014) ‘Miracle cure’ or ‘liquid handcuffs’: Reporting on naltrexone and methadone in the Australian print media. Drug and Alcohol Review 33:5, pages 506-514.
Crossref
Crossref
Briony Larance, Natacha Carragher, Richard P. Mattick, Nicholas Lintzeris, Robert Ali & Louisa Degenhardt. (2014) A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. Drug and Alcohol Dependence 142, pages 46-55.
Crossref
Crossref
George C. Dertadian & Lisa Maher. (2014) From oxycodone to heroin: Two cases of transitioning opioid use in young Australians. Drug and Alcohol Review 33:1, pages 102-104.
Crossref
Crossref
Shanthi Mogali & Sandra D. Comer. 2013. Research and Development of Opioid-Related Ligands. Research and Development of Opioid-Related Ligands
39
60
.
Paul Duffy & Helen Baldwin. (2012) The nature of methadone diversion in England: a Merseyside case study. Harm Reduction Journal 9:1, pages 3.
Crossref
Crossref
Joseph Tkacz, Jamie Severt, John Cacciola & Charles Ruetsch. (2011) Compliance with Buprenorphine Medication‐Assisted Treatment and Relapse to Opioid Use. The American Journal on Addictions 21:1, pages 55-62.
Crossref
Crossref
RICHARD HALLINAN, MARY OSBORN, MILTON COHEN, MALCOLM DOBBIN & ALEX WODAK. (2011) Increasing the benefits and reducing the harms of prescription opioid analgesics. Drug and Alcohol Review 30:3, pages 315-323.
Crossref
Crossref
Anna Kline, Jill M. Williams, Marc L. Steinberg, Dina Mattern, Megan Chesin, Suzanne Borys & Vamsee Chaguturu. (2022) Predictors of Opioid Overdose During the COVID-19 Pandemic: The Role of Relapse, Treatment Access and Non-Prescribed Suboxone. SSRN Electronic Journal.
Crossref
Crossref